FOSTER CITY, Calif.--(BUSINESS WIRE)--

福斯特城，加利福尼亚州——（商业资讯）

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the successful completion of its

吉利德科学公司（纳斯达克代码：GILD）今天宣布其成功完成了

previously announced

之前已宣布

acquisition of Arcellx, Inc. (Nasdaq: ACLX). Under the terms of the transaction, Gilead acquired Arcellx for $115 per share in cash, plus one non‑transferable contingent value right (CVR) of $5 per share, representing a total implied equity value of approximately $7.8 billion at the time of closing..

收购Arcellx, Inc.（纳斯达克股票代码：ACLX）。根据交易条款，吉利德以每股115美元现金收购了Arcellx，另加每股5美元的不可转让或有价值权（CVR），在交易完成时代表约78亿美元的总隐含股权价值。

The acquisition builds on Kite, a Gilead Company, and Arcellx’s successful collaboration and provides Gilead with full control of anitocabtagene autoleucel (anito‑cel), an investigational BCMA‑directed CAR T‑cell therapy for multiple myeloma. By consolidating ownership of anito‑cel and eliminating future profit‑share, milestone and royalty obligations, Gilead is positioned to accelerate development, streamline decision‑making and maximize the long‑term potential of the program..

此次收购建立在吉利德公司旗下的凯特与Arcellx成功合作的基础上，使吉利德完全掌控了anitocabtagene autoleucel（anito‑cel），一种用于多发性骨髓瘤的在研BCMA导向CAR T细胞疗法。通过整合anito‑cel的所有权并消除未来的利润分成、里程碑付款和特许权使用费义务，吉利德能够加速开发进程、简化决策流程，并最大化该计划的长期潜力。

“With the Arcellx acquisition, our focus turns to executing with speed and discipline as we prepare to bring anito‑cel to patients,” said Cindy Perettie, Executive Vice President and Global Head of Kite. “I want to thank the Arcellx team for their scientific leadership, close collaboration to date and deep expertise they bring as we advance anito‑cel.

“随着收购Arcellx，我们的重点转向快速且有纪律地执行，为将anito-cel带给患者做好准备，”Kite的执行副总裁兼全球负责人Cindy Perettie表示。“我要感谢Arcellx团队展现出的科学领导力、迄今为止的密切合作以及他们在推进anito-cel过程中带来的深厚专业知识。”

With this acquisition, anito‑cel and the differentiated D‑Domain BCMA binder will advance within Kite, combining this science with our global manufacturing, regulatory and commercial capabilities to unlock the full value of this potentially transformative therapy for people living with multiple myeloma.”.

“通过此次收购，anito-cel 和差异化的 D 结构域 BCMA 结合剂将在 Kite 内部推进，将这一科学与我们的全球生产、监管和商业能力相结合，充分释放这种潜在变革性疗法对多发性骨髓瘤患者的价值。”

On April 28, 2026, Gilead successfully completed its tender offer for all outstanding shares of common stock of Arcellx and accepted for payment all shares validly tendered and not validly withdrawn as of the expiration time of the tender offer, which shares represented, together with shares already owned by Gilead, approximately 77.2% of Arcellx’s outstanding shares.

2026年4月28日，吉利德成功完成了对Arcellx所有已发行普通股的要约收购，并接受了在要约到期时有效提交且未有效撤回的所有股份的付款，这些股份加上吉利德已经持有的股份，共计约占Arcellx已发行股份的77.2%。

Following completion of the offer, Gilead completed the acquisition of Arcellx through a merger of Gilead’s wholly owned subsidiary with and into Arcellx, in which shares of Arcellx common stock were cancelled and converted into the right to receive the same $115 per share in cash and one CVR of $5 per share as shares tendered in the offer..

在要约收购完成后，吉利德通过将其全资子公司与Arcellx合并完成了对Arcellx的收购，在此次合并中，Arcellx普通股股份被注销并转换为获得与要约中相同的每股115美元现金及每股5美元的一份CVR的权利。

The CVR is payable upon achievement of cumulative global net sales of anito‑cel of at least $6.0 billion from launch through the end of 2029.

CVR 在从推出到 2029 年底期间，anito-cel 的全球累计净销售额达到至少 60 亿美元时到期支付。

As a result of the completion of the merger, Arcellx has become a wholly owned subsidiary of Gilead and the common stock of Arcellx will be delisted from the Nasdaq Global Select Market.

由于合并完成，Arcellx 已成为 Gilead 的全资子公司，且 Arcellx 的普通股将从纳斯达克全球精选市场退市。

This transaction is expected to be accounted for as an asset acquisition and reduce Gilead’s GAAP and non-GAAP 2026 diluted EPS by approximately $5.57 - $5.67. Excluding the impact of acquired in-process research and development expenses, Gilead expects the transaction to be modestly dilutive to earnings per share in 2026 and 2027, and accretive in 2028 and thereafter, subject to FDA approval of anito‑cel..

该交易预计将成为一项资产收购，使吉利德的GAAP和非GAAP 2026年稀释每股收益减少约5.57至5.67美元。剔除所收购的在研研发费用的影响后，吉利德预计该交易将在2026年和2027年小幅稀释每股收益，并在2028年及以后增厚收益，但需取决于anito-cel获得FDA批准的情况。

About Anito-cel

关于Anito-cel

Anitocabtagene autoleucel (anito-cel, previously ddBCMA) is the first BCMA-directed CAR T-cell therapy to be investigated in multiple myeloma that utilizes a novel and compact binder known as the D-Domain. The small, stable D-Domain binder enables high CAR expression without tonic signaling and is designed to quickly release from the BCMA target.

Anitocabtagene autoleucel（anito-cel，之前称为ddBCMA）是首个在多发性骨髓瘤中研究的BCMA导向CAR T细胞疗法，它采用了一种新颖且紧凑的结合剂，称为D结构域。这种小型、稳定的D结构域结合剂能够在无紧张信号的情况下实现高CAR表达，并设计为快速从BCMA靶标上释放。

This combination may allow for the effective elimination of multiple myeloma cells without severe immunotoxicity. Anito-cel has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations by the U.S. Food and Drug Administration..

这种组合可能能够在不造成严重免疫毒性的前提下有效清除多发性骨髓瘤细胞。Anito-cel 已被美国食品药品监督管理局授予快速通道、孤儿药和再生医学高级疗法资格。

About Gilead and Kite Oncology

关于吉利德和风筝肿瘤学

Gilead and Kite Oncology are working to transform how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care.

吉利德和凯特肿瘤学公司正致力于改变癌症的治疗方式。我们通过下一代疗法、组合和技术进行创新，以期为癌症患者带来更好的治疗效果。我们正有目的地构建我们的肿瘤学产品组合和研发管线，以解决医疗领域最大的空白。

From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer..

从抗体药物偶联技术、小分子到基于细胞疗法的方法，我们正在为癌症患者创造新的可能性。

About Gilead Sciences

关于吉利德科学公司

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation.

吉利德科学公司是一家生物制药公司，三十多年来一直致力于医学领域的突破，旨在为全人类创造一个更健康的世界。公司致力于推进创新药物的研发，以预防和治疗危及生命的疾病，包括艾滋病、病毒性肝炎、新冠肺炎、癌症和炎症等。

In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif..

2025年，吉利德宣布计划投资320亿美元，进一步加强其在美国的布局，推动下一个发现、创造就业和公共卫生准备的时代，同时继续在全球范围内进行投资，确保世界各地的患者都能从其科学创新中受益。吉利德在全球35多个国家开展业务，总部位于加利福尼亚州福斯特城。

Forward-Looking Statements

前瞻性声明

This communication contains forward-looking statements related to Gilead, Arcellx and the acquisition of Arcellx by Gilead that are subject to risks, uncertainties, and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of Gilead and Arcellx and members of their respective senior management teams.

本通讯包含与吉利德、Arcellx 以及吉利德收购 Arcellx 相关的前瞻性陈述，这些陈述受风险、不确定性和其他因素的影响。除历史事实陈述之外的所有陈述均可能被视为前瞻性陈述，包括有关吉利德和 Arcellx 及其各自高级管理团队成员的意图、信念或当前期望的所有陈述。

In some cases, forward-looking statements can be identified by the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “seek,” “may,” “plan,” “project,” “should,” “target,” “will,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.

在某些情况下，前瞻性陈述可以通过使用诸如“预期”、“相信”、“估计”、“预计”、“意图”、“寻求”、“可能”、“计划”、“项目”、“应该”、“目标”、“将”或这些术语的否定形式或其他类似表达来识别，尽管并非所有前瞻性陈述都包含这些词语。

Forward-looking statements include, without limitation, statements regarding the transaction and related matters, prospective performance and opportunities, post-closing operations and the outlook for the companies’ businesses, including Gilead’s ability to apply its global manufacturing, regulatory and commercial capabilities and to accelerate the development of anito-cel; regulatory applications; the potential of Arcellx’s cell therapy platform; the impact of the transaction on Gilead’s diluted EPS; and any assumptions underlying any of the foregoing.

前瞻性声明包括但不限于关于交易及相关事项、未来业绩与机遇、交割后运营、公司业务前景的声明，包括吉利德运用其全球生产、监管和商业能力以及加速开发anito-cel的能力；监管申请；Arcellx细胞治疗平台的潜力；交易对吉利德稀释每股收益的影响；以及上述任何内容所基于的假设。

Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.

投资者应注意，任何此类前瞻性陈述都不是未来业绩的保证，且涉及风险和不确定性，投资者被提醒不要过度依赖这些前瞻性陈述。由于诸多风险和不确定性，实际结果可能与目前预期的结果有重大差异。

Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forw.

可能导致实际结果与前瞻性预期不符的风险和不确定性。

Gilead, Kite, Arcellx and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

吉利德、Kite、Arcellx 和吉利德标志是吉利德科学公司或其相关公司的商标。

For more information about Gilead, please visit the company’s website at

有关吉利德的更多信息，请访问公司网站

www.gilead.com

www.gilead.com

, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

，关注吉利德在X/Twitter（@Gilead Sciences）和LinkedIn（@Gilead-Sciences）。

Ashleigh Koss, Media

阿什利·科斯，媒体

Public_affairs@gilead.com

公共事务@gilead.com

Jacquie Ross, Investors

杰基·罗斯，投资者

investor_relations@gilead.com

投资者关系@gilead.com

Source: Gilead Sciences, Inc.

来源：吉利德科学公司